# Medtronic Completes $650M Acquisition of SPR Therapeutics to Expand Non-Opioid Pain Portfolio

> ma · REPORTED · 2026-07-16

On July 16, 2026, Medtronic announced it had completed its $650 million cash acquisition of SPR Therapeutics, adding the FDA-cleared SPRINT Peripheral Nerve Stimulation System — a 60-day minimally invasive non-opioid pain therapy requiring no permanent implant — to its pain therapy portfolio. The deal expands Medtronic's position as the broadest pain therapy portfolio in the industry.

About Medtronic: Medtronic is a global medical technology leader that develops therapies across cardiovascular, neurology, surgical, and diabetes care; SPR Therapeutics was a privately held medtech company and leader in short-term percutaneous peripheral nerve stimulation therapies for chronic and acute pain.

- Company: Medtronic
- Sector: medical devices
- Primary source: https://news.medtronic.com/2026-07-16-Medtronic-completes-acquisition-of-SPR,-expanding-patient-access-to-minimally-invasive,-non-opioid-treatment-of-chronic-and-acute-pain

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.